Amit Khot

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi request reprint Romidepsin for peripheral T-cell lymphoma
    Amit Khot
    Peter MacCallum Cancer Centre, Division of Cancer Medicine, Locked Bag 1, A Beckett St, VIC 8006, Australia
    Expert Rev Hematol 6:351-9. 2013
  2. ncbi request reprint A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation
    Amit Khot
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma Leuk 13:42-7. 2013
  3. ncbi request reprint Panobinostat in lymphoid and myeloid malignancies
    Amit Khot
    Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Expert Opin Investig Drugs 22:1211-23. 2013
  4. ncbi request reprint Romidepsin for cutaneous T-cell lymphoma
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, Division Cancer Medicine, St Andrew s Place, East Melbourne, Australia
    Future Oncol 9:1819-27. 2013
  5. ncbi request reprint Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
    Charlotte F M Hughes
    Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
    Blood 125:71-81. 2015

Collaborators

  • H Miles Prince
  • Peter Gambell
  • Charlotte F M Hughes
  • Colin Wood
  • Stephen Lade
  • Kate Newland
  • Gail Ryan
  • Michael Dickinson
  • Constantine Tam
  • Christopher McCormack
  • David A Westerman
  • Robert Twigger
  • Odette Buelens
  • David Ritchie

Detail Information

Publications5

  1. ncbi request reprint Romidepsin for peripheral T-cell lymphoma
    Amit Khot
    Peter MacCallum Cancer Centre, Division of Cancer Medicine, Locked Bag 1, A Beckett St, VIC 8006, Australia
    Expert Rev Hematol 6:351-9. 2013
    ....
  2. ncbi request reprint A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation
    Amit Khot
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma Leuk 13:42-7. 2013
    ..We prospectively explored a strategy that used prophylactic delayed filgrastim only in patients with risk factors...
  3. ncbi request reprint Panobinostat in lymphoid and myeloid malignancies
    Amit Khot
    Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Expert Opin Investig Drugs 22:1211-23. 2013
    ..Activity has been demonstrated in hematological diseases, such as cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma (HL), myeloma and myeloid malignancies...
  4. ncbi request reprint Romidepsin for cutaneous T-cell lymphoma
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, Division Cancer Medicine, St Andrew s Place, East Melbourne, Australia
    Future Oncol 9:1819-27. 2013
    ..Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side-effect profile...
  5. ncbi request reprint Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
    Charlotte F M Hughes
    Division of Haematology and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
    Blood 125:71-81. 2015
    ..00001 and P = .01, respectively). This study confirms that all chemotherapy regimens assessed have very modest efficacy; we recommend their use be restricted until other options are exhausted. ..